New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTUIS, PFE, PSUN, SI, SLB, BHI, TDG, TPH, EV, OHI, MXIM, LVS, BLK, LNG, LLY, FNP, JNJ, KIM, BMRN, BP, ATIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Allegheny Technologies (ATI) downgraded to Hold from Buy at Deutsche Bank... BP (BP) downgraded to Neutral from Outperform at Exane BNP Paribas... BioMarin (BMRN) downgraded to Equal Weight from Overweight at Barclays... BlackRock (BLK) downgraded to Neutral from Buy at Goldman... Cheniere Energy (LNG) downgraded to Neutral from Buy at Citigroup... Eli Lilly (LLY) downgraded to Underweight from Equal Weight at Barclays... Fifth & Pacific (FNP) downgraded to Hold from Buy at Brean Capital... Johnson & Johnson (JNJ) downgraded to Equal Weight from Overweight at Barclays... Kimco Realty (KIM) downgraded to Sell from Neutral at UBS... Las Vegas Sands (LVS) downgraded to Market Perform from Outperform at FBR Capital... Maxim Integrated (MXIM) downgraded to Perform from Outperform at Oppenheimer... Omega Healthcare (OHI) downgraded to Sell from Neutral at UBS... Pacific Sunwear (PSUN) downgraded to Neutral from Buy at Janney Capital... Pfizer (PFE) downgraded to Market Perform from Outperform at Cowen... Siemens (SI) downgraded to Neutral from Buy at BofA/Merrill... Schlumberger (SLB) downgraded to Sector Perform from Outperform at Iberia... Baker Hughes (BHI) downgraded to Sector Perform from Outperform at Iberia... TransDigm (TDG) downgraded to Neutral from Buy at DA Davidson... TRI Pointe Homes (TPH) downgraded to Market Perform from Outperform at FBR Capital... Eaton Vance (EV) downgraded at Susquehanna... Unisys (UIS) downgraded to Neutral from Positive at Susquehanna.
News For ATI;BP;BMRN;BLK;LNG;LLY;FNP;JNJ;KIM;LVS;MXIM;OHI;PFE;PSUN;SI;SLB;BHI;TDG;TPH;EV;UIS From The Last 14 Days
Check below for free stories on ATI;BP;BMRN;BLK;LNG;LLY;FNP;JNJ;KIM;LVS;MXIM;OHI;PFE;PSUN;SI;SLB;BHI;TDG;TPH;EV;UIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 21, 2014
08:02 EDTPFEPfizer initiates U.S. EAP for palbociclib.
Pfizer announced that the company has initiated a multi-center, open-label expanded access program in the U.S. for palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer for whom letrozole is considered appropriate therapy.
07:55 EDTPFEActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTPFEPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
09:00 EDTEVEaton Vance CEO sees "improved organic growth in the coming quarters"
Eaton Vance CEO Thomas Faust Jr., stated, "Although flows remain disappointing, continued development of emerging franchises and strong investment performance support improved organic growth in the coming quarters."
08:58 EDTEVEaton Vance reports Q3 adjusted EPS 63c, consensus 62c
Reports Q3 revenue $367.6M, consensus $365.29M.
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
August 19, 2014
15:16 EDTEVNotable companies reporting before tomorrow's open
Subscribe for More Information
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTPFE, LLY, JNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:29 EDTMXIMGoldman cuts sector view on semiconductors to Cautious
Subscribe for More Information
10:01 EDTMXIMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:36 EDTTPHTRI Pointe Homes acquires 649 lots for seven new communities
TRI Pointe (TPH) announced the acquisition of 649 lots for seven new communities in markets across the country, expanding its presence in California, Nevada, Washington state and Virginia. This comes on the heels of TRI Pointe’s $2.8B merger with Weyerhaeuser’s (WY) home-building subsidiary, Weyerhaeuser Real Estate.
08:04 EDTMXIMSemiconductors sector downgraded to Cautious from Neutral at Goldman
Goldman downgraded the Semiconductors sector to Cautious given signs the cycle is turning based on expectations for a slowdown in semiconductor revenue growth, above trend semi unit shipments that should normalize, and stretching lead times. As a result, the analyst sees risk to Q4 estimates and sees further downside of 10%-25% for the SOX (SOX) and downgraded NXP Semiconductors (NXPI) to Sell from Neutral, InvenSense (INVN) to Neutral from Buy, and removed Maxim Integrated (MXIM) from the Conviction Buy List.
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTPFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
07:48 EDTMXIMMaxim Integrated downgraded to Buy from Conviction Buy at Goldman
Subscribe for More Information
August 17, 2014
17:42 EDTSLBSchlumberger should see profits increase, Barron's says
Schlumberger should see profits increase as the company focuses on its North American business, Barron's contends in its cover article. Reference Link
August 15, 2014
13:04 EDTBHIBaker Hughes reports U.S. rig count up 5 to 1913 rigs
Baker Hughes announced that the U.S. Rig Count is up 5 rigs from last week to 1913, with oil rigs up 1 to 1589, gas rigs up 5 to 321, and miscellaneous rigs down 1 to 3. Says the U.S. Rig Count is up 122 rigs from last year at 1791, with oil rigs up 192, gas rigs down 67, and miscellaneous rigs down 3. The U.S. Offshore rig count is 62, unchanged from last week, and unchanged year over year.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use